Jane Street Group LLC Grows Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Jane Street Group LLC grew its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 28.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 65,373 shares of the company's stock after acquiring an additional 14,434 shares during the quarter. Jane Street Group LLC owned 0.13% of Prestige Consumer Healthcare worth $4,713,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in PBH. Lombard Odier Asset Management USA Corp bought a new stake in shares of Prestige Consumer Healthcare in the second quarter valued at approximately $550,000. Sequoia Financial Advisors LLC raised its holdings in Prestige Consumer Healthcare by 12.9% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company's stock worth $708,000 after purchasing an additional 1,120 shares during the last quarter. Pinnacle Associates Ltd. raised its position in shares of Prestige Consumer Healthcare by 60.3% in the 3rd quarter. Pinnacle Associates Ltd. now owns 24,630 shares of the company's stock worth $1,776,000 after acquiring an additional 9,269 shares in the last quarter. Ariel Investments LLC grew its position in shares of Prestige Consumer Healthcare by 10.7% during the 2nd quarter. Ariel Investments LLC now owns 2,835,203 shares of the company's stock worth $195,204,000 after buying an additional 274,212 shares during the period. Finally, Citigroup Inc. grew its holdings in Prestige Consumer Healthcare by 66.6% in the third quarter. Citigroup Inc. now owns 76,772 shares of the company's stock worth $5,535,000 after purchasing an additional 30,677 shares during the period. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Trading Up 0.1 %

Shares of PBH stock traded up $0.08 on Wednesday, hitting $80.47. 79,668 shares of the company's stock traded hands, compared to its average volume of 251,520. The company's fifty day simple moving average is $78.65 and its 200 day simple moving average is $72.86. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. Prestige Consumer Healthcare Inc. has a one year low of $57.95 and a one year high of $86.36. The stock has a market capitalization of $3.98 billion, a price-to-earnings ratio of 19.56, a P/E/G ratio of 2.32 and a beta of 0.49.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. During the same quarter in the previous year, the company posted $1.07 earnings per share. The business's revenue was down .9% on a year-over-year basis. Equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.44 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. StockNews.com lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Tuesday, December 10th. Sidoti cut Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective on the stock. in a research note on Monday, December 9th. DA Davidson reiterated a "buy" rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Finally, Jefferies Financial Group reissued a "hold" rating and issued a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of "Hold" and an average target price of $85.25.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, insider William P'pool sold 8,987 shares of the firm's stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now directly owns 20,058 shares in the company, valued at $1,641,747.30. This trade represents a 30.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares of the company's stock, valued at $26,510,635.20. This represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,810 shares of company stock worth $3,187,300. 1.60% of the stock is currently owned by insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.